Morten Schlein

Morten Schlein has extensive experience in the pharmaceutical industry, working in various roles at Gubra and Novo Nordisk. Morten has been involved in important projects such as the development and commercialization of an insulin/GLP-1 co-formulation. With a background in Molecular Biology and Biochemistry, Morten has made significant contributions to the field through their research on peptide physical stability and formulation optimization. Morten's expertise and achievements in drug development and project management have been recognized both internally and externally.